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Ltd. This is an open access article unAbstract Transoral robotic surgery is a exciting field that continues to develop and push the
boundaries of current procedural ability and challenges historical treatment paradigms. With
the first use of a surgical robot in 1985, to the first clinical use of the robot transorally in 2005,
there was some lag in adoption of robotic techniques in the head and neck region. However,
since 2005 transoral robotic surgery has rapidly gained momentum amongst head and neck sur-
geons. With FDA approval of the da Vinci robot in 2009, transoral robotic surgery is currently
offered as a treatment modality for malignant and nonmalignant disease of the head and neck
region. This new technology is being used to reconsider historical treatment paradigms for ma-
lignancies of the upper aerodigestive tract due to the fact that minimally invasive surgical ac-
cess to the oropharynx and larynx has been improved. Along with this enhanced access have
come innovative procedures and uses of the technology for multiple facets of head and neck
disease. Technology continues to improve and innovation in surgical robotics is expected to
continue as more companies attempt to capture this market. This article aims to provide a
view at the landscape of transoral robotic surgery and explore the future frontiers.
Copyright ª 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on
behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The use of robotic surgical systems in the operating room
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Medical Association. Production a
der the CC BY-NC-ND license (httpwas used to perform targeted neurosurgical procedures.1
Throughout the 1980’s the interest in the use of robotic
systems continued to grow and technology advanced to the
point where several commercial systems were developed,
namely the AESOP robotic camera positioning device for
endoscopes,2 and the da Vinci surgical system. As time went
on, the da Vinci system became the leader in the field and is
the most prevalent robotic system in use today. The surgical
robot has been widely applied in multiple specialties
including urologic, gynecologic, orthopedic, thoracic, gen-
eral surgery, cardiothoracic, and head and neck surgery.
The adoption of robotic technology by the head and neck
surgery community did not occur until 2003 (Fig. 1), whennd hosting by Elsevier B.V. on behalf of KeAi Communications Co.,
://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1 Timeline of transoral robotic surgery.
Transoral robotic surgery frontiers 131Haus et al3 studied the use of the robot for head and neck
procedures (submandibular gland excision, parotidectomy,
neck dissection, and thymectomy) in pigs. It was in 2005
that McLeod and Medler4 first used the robot in a human
patient to remove a vallecular cyst. The University of
Pennsylvania had also conducted preclinical studies using
the surgical robot for pharyngeal and laryngeal surgery in
cadavers and canines in the early 2000’s,5e7 and in 2006 a
case series of three patients who underwent TORS for
tongue base squamous cell carcinoma was reported by
O’Malley et al8 demonstrating safety and efficacy of TORS.
Since then there have been numerous reports from multiple
institutions demonstrating the safety and efficacy of TORS
for radical tonsillectomy, tongue base resection, and
supraglottic laryngectomy. These procedures are being
offered as treatment options for resectable malignancies in
these subsites. As technology extends the ability of the
surgeon to safely and effectively operate in the
oropharynx, larynx, and hypopharynx, the role of surgery in




There have been several recent developments that have
led to a renewed interest in surgically managing oropha-
ryngeal malignancies. First, TORS allows for improved
visualization and the ability to resect lesions en bloc in the
oropharynx. Second, the biology of oropharynx cancer is
better understood. As we continue to gain insights on therole of the human papilloma virus (HPV) in oropharyngeal
cancer the role of surgical management of this disease re-
mains to be fully understood.
In 1991 the VA larynx study which demonstrated the
equal survival between patients receiving chemoradiation
therapy vs. patients undergoing laryngectomy followed by
radiation.9 This lead to increased interest in avoiding sur-
gery in order to preserve function and these protocols were
applied to other subsites in the head and neck. In 2002,
Mendenhall et al conducted a large retrospective study of
patients treated for oropharyngeal cancer at 51 in-
stitutions. This landmark study demonstrated equal effec-
tiveness of radiation therapy to surgery in the treatment of
oropharynx cancer and increased severe or fatal compli-
cations in patients that underwent surgery and radiation
therapy.10 This solidified the place of radiation therapy as
the treatment of choice for oropharyngeal cancer and
somewhat marginalized the role of surgery.
However, in smaller studies, transoral laser microsurgery
(TLM), a precursor to TORS, was shown by Steiner et al11 in
2003 to have local control rates around 85% at 5 years and
spared patients radiation 52% of the time. Haughey et al12
published 5 year survival of 79% and local control rate of
97% in 2011 in a series of 204 patients. This suggests that
this type surgical therapy might be as effective as radiation
therapy and eliminate the associated toxicities. There have
been no randomized controlled studies of surgery vs. radi-
ation therapy in the treatment of oropharynx cancer. At
this time, work began at the University of Pennsylvania on
utilizing the da Vinci robot for transoral robotic surgery and
several small series of patients with oropharynx and
supraglottic cancers resected via a TORS approach were
published. By 2009, the FDA granted approval for the use of
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case series from major institutions have been published.
Overall results suggest adequate safety, equivalent onco-
logic outcomes, and improved functional outcomes as
compared to open surgery and radiation therapy.13e18
As the connection between HPV and oropharyngeal
cancer emerged, there was increasing awareness that the
population of patients affected by HVP positive oropha-
ryngeal cancer was young and healthy and these patients
have increased survival as compared to patients with HPV
negative disease (82% vs. 57% respectively).19 These tumors
respond well to radiation therapy, however there is
increasing concern of the long-term effects of radiation
therapy in this young and otherwise healthy cohort.
Therefore interest in being able to treat these patients
surgically and sparing them adjuvant radiation therapy has
been renewed. Recently, Olsen et al reported a series of 18
patients with HPV positive, T1eT3, N0eN2a, oropharyngeal
cancer treated with TORS and neck dissection alone. These
patients had 3-year survival of 100% and recurrence free
survival of 91%.20 Deintensification of therapy in HPV posi-
tive patients is currently being studied in the ECOG 3311
trial. The results of this important trial should help to direct
therapy that is appropriate while limiting the functional
deficits caused by treatment. The trial sets a framework for
future studies investigating the issue of deintensification of
therapy.
Perhaps the most compelling data evaluating TORS vs.
radiation therapy is a 2014 systematic published by Genden
et al.21 8 IMRT and 12 TORS case series were included in the
analysis. They found equivalent 2-year survival ranging
from 84% to 96% in the IMRT studies and 82%e94% in the
TORS studies. Thus indicating TORS may be equivalent to
IMRT. Further investigation with a prospective trial as well
as longer follow up of these patients is needed to better
understand the survival and functional outcomes of TORS.
As clinical experience with the robot has grown, sur-
geons have been working to better understand the in-
dications for its use, and large centers have been operating
on more advanced disease and performing more extensive
dissection. Weinstein et al22 published a prospective cohort
study of 47 patients from the University of Pennsylvania on
TORS outcomes in patients with advanced (stage III and VI)
oropharyngeal cancers. This study included 9 patients with
T3 and 2 patients with T4 disease. Overall disease free
survival was 90% at two years. 18 of 47 (38%) patients were
spared chemotherapy, and 5 of 47 (11%) patients were
spared radiation therapy as well. Only 1 patient remained
PEG tube dependent at the end of 1 year.
Another area that TORS has been shown to be potentially
useful is in carcinomas of unknown primary sites (CUP).
Despite thorough workup of patients who present with
metastatic carcinoma in cervical lymph nodes, about 2% of
patients will not have a localizable primary site of dis-
ease.23,24 Determining the origin of the carcinoma allows
for narrowing of radiation fields and reducing doses, thus
limiting toxicity of treatment. Some patients may also be
candidates for surgical management alone if the primary is
resected with negative margins and the neck disease can be
managed surgically. Karni et al25 showed in a 2011 study
that the use of TLM allowed identification of the unknown
primary site in 95% of patients. Nagel et al26 published aslightly lower rate of primary site detection of 86%, but
identification of the primary is far better with these surgi-
cal methods as compared to imaging and standard direct
laryngoscopy with biopsy alone. With similar principles in
mind, several studies have now been published using TORS
as part of the workup and treatment algorithm for CUP. The
robot allows improved 3D visualization of the collapsible
tissues in the oropharynx and allows for enhanced visuali-
zation of subtle mucosal changes associated with sub-
centimeter primary lesions. Mehta et al27 showed that in
patients with CUP, when all other workup was negative
(PET/CT, tonsillectomy, and thorough endoscopy with bi-
opsies), robotic tongue base resection located 90% of the
previously unknown primaries in the tongue base. Patel
et al28 demonstrated a similar benefit of TORS for identi-
fying elusive primary lesions. Utilizing a TORS approach, the
authors were able to identify 72.2% of primary sites in pa-
tients with no radiographic or clinical evidence of disease.
The Ohio State University group reported a series of 22,
that 13/17 patients whose tumors were identified using a
TORS approach were removed with negative margins. Prior
studies of CUP, not utilizing TLM or TORS, have shown that
use of panendoscopy, tonsillectomy, and directed biopsies
have only led to the identification of a primary site in about
20% of patients with no clinical or radiological evidence of
disease.29,30 A cost effectiveness study from the University
of Pittsburgh indicates that including a TORS tongue base
resection may be a cost effective procedure during the
initial exam under anesthesia.31 Again, larger series and
prospective studies are needed to further define the role of
TORS in CUP, however based on these initial findings, the
technique appears to be a valuable tool for both working up
and treating these patients.Procedural frontiers
One of the advantages of TORS has been the ability to
resect lesions of the upper aerodigestive tract without
entering the neck, often eliminating the need for recon-
structive procedures and mitigating the risk of phar-
yngocutaneous fistula. However, there may be a role for
reconstruction in these patients to help the ultimately
achieve better functional outcomes and to protect exposed
structures, such as the carotid artery, from oral secretions.
Traditionally, the tongue base, oropharynx, and supra-
glottic larynx have been difficult areas to reconstruct and
open techniques for access often require mandibulotomy
and lip splitting incisions. With the robot, surgeons have
been able to visualize these areas and successfully inset
free flaps in a minimally invasive manner. The indications
and the benefits of transoral robotic reconstruction remain
for further investigation.32e37
While TORS tonsillectomy, tongue base resection, and
supraglottic laryngectomy are the three most common ro-
botic applications in the head and neck malignancy, case
reports and small series describing resection in other
anatomic subsites have been reported. In 2008, Ozer and
Waltonen38 were the first to describe nasopharyngectomy
in a cadaver, an approach which also allows access to the
clivus and upper cervical vertebrae. O’Malley et al39 were
the first to publish on a TORS approach to pharyngeal space
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placement of transcervical suprahyoid oropharyngeal ports
can further expand the surgical access to include the skull
base.40e43
Robotic supraglottic laryngectomy (Fig. 2) has now
become a relatively standard procedure amongst TORS
surgeons, however compared to oropharyngeal TORS there
is substantially less data. Ozer et al44 published a case se-
ries of 13 patients who underwent TORS supraglottic lar-
yngectomy demonstrating safety and good functional
outcomes. Survival data in this population is limited, with
Mendelsohn et al45 reporting 2 year survival data in 18 pa-
tients (local regional control 83%, disease specific survival
100%, overall all survival 89%). Park et al46 showed a 2-year
disease free survival rate of 91%. These patients were
matched to a cohort of patients who underwent open
supraglottic laryngectomy and the TORS group demon-
strated earlier oral feeding, decreased time to dec-
annulation, and decreased hospital stay.
Several reports of expanding the use of the robot in
laryngeal cancer beyond the supraglottic laryngectomy
have now been published. In 2013 Smith et al published a
multi institutional case series of 7 patients who underwent
attempted transoral robotic laryngectomy. Five of the
procedures were completed successfully, while two
required conversion to an open approach. The authors
suggested that this procedure might be particularlyFig. 2 A. Intraoperative view of supraglottic squamous cell
carcinoma on the laryngeal surface of the epiglottis. This
tumor extended from the tip of the epiglottis to just superior
to the anterior commissure. B. Postoperative appearance after
TORS supraglottic laryngectomy showing preserved true vocal
cords anteriorly and arytenoids posteriorly. The epiglottis,
aryepiglottic folds, false vocal cords, and ventricular mucosa
has been resected.valuable in surgical salvage patients and in patients with
nonfunctional larynx after radiation therapy. The limited
dissection is proposed to potentially lead to fewer wound
healing complications.47,48 Further study is required before
this technique will become widely endorsed.
What is the limit to the frontier of transoral robotic
surgery? Weinstein et al49 suggested limits in 2015 with a
published set of contraindications for TORS. They suggest
vascular, functional, oncological and non-oncological con-
traindications to TORS based on their experience with 1400
TORS cases. They assert that TORS is not a modality
designed to push the surgical envelope; rather TORS should
be used as a tool. TORS procedures being performed by
head and neck surgeons should be reproducible, teachable,
and have predictable outcomes.Technological frontiers
There is continued interest in expanding the role of robotic
surgery within head and neck surgery, and many of the
limitations have been technical. Commonly used mouth
gags for exposure are the Feyh-Kastenbauer-Weinstein-
O’Malley retractor or the Crowe-Davis mouth gag. New re-
tractors designed specifically for TORS are hitting the
market. The LARS retractor by FENTEXmedicala and the
MedRobotics Flex retractorb are now available, and other
retractors are in development. Having several retractor
options may improve the ability to expose the surgical site
in a wider variety of patients.
Several new robotic platforms are emerging at this time.
In the daVinci line of robots, the S and Si platforms have
been widely utilized for TORS. In 2014, da Vinci released a
new robotic system, the Xi, which has a different arm
configuration that allows for more freedom in positioning
the robotic arms.c This system has already been found
useful in abdominal and thoracic procedures, however its
use in the head and neck has been limited by lack of FDA
approval for TORS. Several centers are investigating its use
and are optimistic that it may have advantages as
compared to the S and Si systems. Furthermore, this system
has the ability to perform fluorescence imaging; a feature
that with specially designed pharmaceuticals injected
intravenously prior to surgery or applied topically may help
with identification of tumors and improve the ability to
visualize tumor margins. Several preclinical studies have
shown feasibility of such an approach.50e52
With high volumes of abdominal and pelvic robotic sur-
gery as compared to TORS, many of the technological de-
velopments have been aimed to improve these procedures.
The desire to limit the number of access ports required for
these procedures has led to the development of a single
port system by da Vinci. This system consists of a single
rigid port from which four flexible arms extend, three in-
struments arms and one flexible endoscope. The in-
struments are steered into position by the surgeon. The
single port is much larger than any of the currently utilized
da Vinci instruments, at 24 mm, however may be beneficial
for transoral procedures.d The ability to successfully
perform oropharyngeal surgery using this system has been
demonstrated in cadaver studies. The authors also noted
that the single port design increased the room at the head
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site.53 Currently, this device is only FDA approved for spe-
cific urological procedures, but the approval is expected to
broaden to cover head and neck application.
Another surgical robot has also recently entered the
market to compete with the Da Vinci robot. The Flex ro-
botic system from MedRobotics was FDA approved for
transoral use in July of 2015. This robotic system is unique
as it is a flexible snake like device that can be steered to
the operative site rather than having rigid arms like the da
Vinci robot. Once in position, there are two dissection
arms, on either side of a high definition endoscope, which
can be used to manipulate tissue.e This robot has had
limited use thus far, however there are increasing case
reports and series being reported since its FDA
approval.54,55
Titan Medical, a Canadian based company, has also
developed a single port robotic system, the SPORT Surgical
System. They are expected to enter the commercial market
in the US in 2017.f Google and Ethicon also announced a
collaboration to develop a surgical robotics system with a
start up company coined Verb.g A key feature of their
proposed robotic system is haptic feedback, which is a
feature the da Vinci does not provide.
There are several other useful technologies yet to be
incorporated in commercially available surgical robotic
systems. One such feature would be the use of image
guidance and navigation features such as 3D overlays on the
endoscopic images to identify vascular, neural, or other key
structures. End effectors able to remove bone such as drills
or ultrasonic devices would enhance the ability of the robot
to be used transorally at the skull base and cervical spine,
thus further expanding the usefulness of these systems.40Conclusion
With further innovation, the ability of robotic surgical sys-
tems to assist surgeons will continue to expand. With the
ECOG 3311 trial setting the groundwork for surgical trials
investigating TORS and TLM, further clinical studies will be
key in better defining the role of these techniques in
treatment of patients. As surgical experience utilizing the
robot and technological capabilities grow, new procedures
and approaches will be developed that further the scope of
transoral robotic surgery. Several competitors have now
emerged in the field of surgical robotics. Companies will
have to continue to innovate in order to compete and
competition may help control cost and improve the quality
of these products.References
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